These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 1361570)

  • 61. Self-inhibitory dopamine-receptors and central effects of apomorphine.
    Di Chiara G; Porceddu ML; Morelli M; Gessa GL
    Ann Ist Super Sanita; 1978; 14(1):111-22. PubMed ID: 756166
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The involvement of serotonin in the mechanism of central action of apomorphine.
    Grabowska M
    Pol J Pharmacol Pharm; 1976; 28(4):389-94. PubMed ID: 790347
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies.
    Sorensen SM; Kehne JH; Fadayel GM; Humphreys TM; Ketteler HJ; Sullivan CK; Taylor VL; Schmidt CJ
    J Pharmacol Exp Ther; 1993 Aug; 266(2):684-91. PubMed ID: 8102646
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Central antidopaminergic properties of 2-bromolisuride, an analogue of the ergot dopamine agonist lisuride.
    Wachtel H; Kehr W; Sauer G
    Life Sci; 1983 Dec; 33(26):2583-97. PubMed ID: 6607392
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Effects of an ergot derivative, lisuride, on the central dopaminergic system -- studies of behavioral pharmacology].
    Hara K; Ikoma Y; Oshino N
    Nihon Yakurigaku Zasshi; 1982 Jul; 80(1):1-13. PubMed ID: 7173731
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dopamine D-2 receptor agonist-induced behavioural depression: critical dependence upon postsynaptic dopamine D-1 function. A behavioural and biochemical study.
    Jackson DM; Ross SB; Larsson LG
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Oct; 340(4):355-65. PubMed ID: 2573842
    [TBL] [Abstract][Full Text] [Related]  

  • 67. (5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones . A series of novel potential antipsychotic agents.
    Wise LD; Butler DE; DeWald HA; Lustgarten D; Coughenour LL; Downs DA; Heffner TG; Pugsley TA
    J Med Chem; 1986 Sep; 29(9):1628-37. PubMed ID: 2875184
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pre- and postsynaptic dopaminergic activities of U-86170F.
    Lahti RA; Evans DL; Figur LM; Huff RM; Moon MW
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Nov; 344(5):509-13. PubMed ID: 1687420
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Synthesis and dopamine agonist properties of (+-)-trans-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano [4,3-b]-1,4-oxazin-9-ol and its enantiomers.
    DeWald HA; Heffner TG; Jaen JC; Lustgarten DM; McPhail AT; Meltzer LT; Pugsley TA; Wise LD
    J Med Chem; 1990 Jan; 33(1):445-50. PubMed ID: 1967318
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dopamine agonist activity of EMD 23,448.
    Martin GE; Pettibone DJ
    J Neural Transm; 1985; 61(1-2):115-23. PubMed ID: 4038993
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Differential effects of haloperidol decanoate, a long-acting neuroleptic, in behavioral and biochemical tests.
    Oka M; Karasawa T; Ochi Y; Asano K; Terauchi Y; Kadokawa T
    Arch Int Pharmacodyn Ther; 1985 Oct; 277(2):289-302. PubMed ID: 4062440
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Neuropharmacological profile of a new series of dopamine agonists: N-n-propyl-hexahydronaphthoxazines.
    Hazelhoff B; De Vries JB; Dijkstra D; Mulder TB; Timmermans PB; Wynberg H; Horn AS
    Eur J Pharmacol; 1986 May; 124(1-2):93-106. PubMed ID: 3720849
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Preclinical neurochemical and electrophysiological profile of 1192U90, a potential antipsychotic.
    Jones-Humble SA; Durcan MJ; Lyerly D; Norton RM; Tang FL; Russell AV; Watson MJ; Gengo PJ; Morgan PF; Wang CM; Cooper BR; Cox RF
    Neuropsychopharmacology; 1996 Sep; 15(3):217-30. PubMed ID: 8873105
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Identification, characterization and pharmacological profile of three metabolites of (R)-(+)-1,2,3,6-tetrahydro-4-phenyl-1-[(3-phenylcyclohexen-1- yl)methyl]pyridine (CI-1007), a dopamine autoreceptor agonist and potential antipsychotic agent.
    Wright JL; Downing DM; Feng MR; Hayes RN; Heffner TG; MacKenzie RG; Meltzer LT; Pugsley TA; Wise LD
    J Med Chem; 1995 Dec; 38(26):5007-14. PubMed ID: 8544176
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Small doses of apomorphine and chronic administration of d-amphetamine reduce locomotor hyperactivity produced by radiofrequency lesions of dopaminergic A10 neurons area.
    Stinus L; Gaffori O; Simon H; Le Moal M
    Biol Psychiatry; 1977 Dec; 12(6):719-32. PubMed ID: 563741
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment.
    Hinzen D; Hornykiewicz O; Kobinger W; Pichler L; Pifl C; Schingnitz G
    Eur J Pharmacol; 1986 Nov; 131(1):75-86. PubMed ID: 3816949
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Is dopamine antagonism a requisite of neuroleptic activity?
    Greenblatt EN; Coupet J; Rauh E; Szucs-Myers VA
    Arch Int Pharmacodyn Ther; 1980 Nov; 248(1):105-19. PubMed ID: 6111298
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Antagonism between L-DOPA and apomorphine in their effects on rat behavior].
    Allikmets LKh; Zharkovskiĭ Am; Vasar EE
    Biull Eksp Biol Med; 1977 Jul; 84(7):51-3. PubMed ID: 560890
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.
    Mierau J; Schingnitz G
    Eur J Pharmacol; 1992 May; 215(2-3):161-70. PubMed ID: 1356788
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats.
    Arnt J; Hyttel J
    J Neural Transm; 1984; 60(3-4):205-23. PubMed ID: 6441835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.